Jidinum

Sitagliptin, the active ingredient in Jidinum, is a dipeptidyl‑peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adult patients with type 2 diabetes mellitus, often in combination with diet and exercise.

GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines. The company adheres to stringent regulatory standards and ensures consistent product availability across global markets. Our distribution network includes major healthcare institutions and specialty pharmacies.

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels as monotherapy. - Combination with metformin: enhances overall glycaemic control when metformin alone is insufficient. - Adjunct to insulin: reduces required insulin dose and mitigates hypoglycaemia risk. - Use with diet and exercise: supports blood sugar management alongside lifestyle modifications. - Combination with sulfonylureas: provides additional glucose‑lowering effect, but requires monitoring for hypoglycaemia.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms of cough and congestion. - Nausea: occasional stomach upset. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort in the abdomen.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including angioedema or anaphylaxis. - Joint pain: unexplained arthralgia. - Hepatic injury: abnormal liver function tests. - Bullous pemphigoid: rare skin blistering disorder. - Hypoglycaemia: especially when combined with insulin or sulfonylureas.

Before initiating therapy, consider the following precautions: - Renal function: assess creatinine clearance and adjust dose if necessary. - Hepatic impairment: use with caution in patients with moderate liver disease. - Concomitant sulfonylureas or insulin: monitor for hypoglycaemia and adjust therapy. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Elderly patients: start at lower dose and monitor for adverse events. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Sitagliptin may interact with several medicines. Review the following groups: Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia – avoid dose escalation without monitoring. - Rifampin: strong enzyme inducer that may reduce sitagliptin exposure – avoid concurrent use. Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium levels. - Diuretics: watch for electrolyte disturbances. - Warfarin: may increase INR – check coagulation parameters regularly. - Digoxin: potential increase in serum digoxin concentration – monitor levels.